In a comprehensive analysis of seven observational studies on treatments for RA, with a total population of 177,963 patients with RA, the risk of lymphoma among patients receiving anti-TNF-α agents was compared with the risk of ones receiving conventional therapy (Table 2). The gene discussed is TNF; the disease is rheumatoid arthritis.